The European Association for the Study of the Liver (EASL) announced on the 21st of April 2017 that the ALIVER project will be presented at the International Liver Congress in Amsterdam.
Albutec is part of the ALIVER consortium.
The project is funded by the EU in the context of the Horizon 2020 research program with a total of € 7.8 million. Work on ALIVER began on 1 January 2017 and will end on 30 September 2020.
The treatment concept of liver failure includes the substitution of functionally impaired patient albumin with pharmaceutical album solution. The stabilizers (octanoate, N-acetyltryptophanate) present in industrial albumin solution impair the binding function of the albumin to be infused and would represent an additional burden on the liver patient. The stabilizers can be removed by means of Hepalbin adsorbers. The Hepalbin treated albumin solution is free from substances which need to be metabolized in the liver and it has a greatly improved capacity to bind endogenous and exogenous liver toxins in the patient.
More information about the project can be found here:Http://aliver.info/about/